Compare FCPT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCPT | BEAM |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2015 | 2019 |
| Metric | FCPT | BEAM |
|---|---|---|
| Price | $25.48 | $26.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | $27.80 | ★ $49.13 |
| AVG Volume (30 Days) | 772.2K | ★ 1.7M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.73% | N/A |
| EPS Growth | 1.87 | ★ 82.31 |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $294,132,000.00 | $24,000.00 |
| Revenue This Year | $6.47 | N/A |
| Revenue Next Year | $8.15 | $35.80 |
| P/E Ratio | $23.49 | ★ N/A |
| Revenue Growth | 9.72 | ★ 33.33 |
| 52 Week Low | $22.78 | $13.53 |
| 52 Week High | $28.98 | $36.44 |
| Indicator | FCPT | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 43.87 |
| Support Level | $25.24 | $23.84 |
| Resistance Level | $25.98 | $29.06 |
| Average True Range (ATR) | 0.41 | 1.96 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 48.02 | 14.79 |
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.